Catalent, Inc. (Catalent) (NYSE:CTLT), the leading global provider of
advanced delivery technologies and development solutions for drugs,
biologics and consumer health products, today announced that it has
completed the acquisition of Accucaps Industries Limited (Accucaps), the
Canada-based developer and manufacturer of Over-the-Counter (OTC),
high-potency and conventional pharmaceutical softgels. Financial details
of the transaction have not been disclosed.
The acquisition substantially complements Catalent’s global OTC and
prescription pharmaceutical softgel capabilities and capacity adding a
portfolio of products supplied to pharmaceutical companies in North
America, and two state-of-the-art facilities offering integrated softgel
development, manufacturing and packaging, thus strengthening Catalent’s
ability to offer its customers turnkey solutions.
Accucaps’ over 500 employees, at its two facilities in Windsor and
Strathroy, Ontario, join Catalent’s global network of 11 Softgel
Technologies facilities. The Accucaps facilities house sizeable
blistering, bottling and other packaging capabilities, as well as
high-potency prescription softgel development and manufacturing
expertise that are complementary to Catalent’s.
Notes for Editors
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs over 9,500
people, including over 1,400 scientists, at more than 30 facilities
across five continents, and in fiscal 2016 generated $1.85 billion in
annual revenue. Catalent is headquartered in Somerset, New Jersey. For
more information, visit www.catalent.com.
Forward-Looking Statements
This release contains both historical and forward-looking statements.
All statements other than statements of historical fact are, or may be
deemed to be, forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements generally can be identified by the use of statements that
include phrases such as “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “plan,” “project,” “foresee,” “likely,” “may,” “will,”
“would” or other words or phrases with similar meanings. Similarly,
statements that describe the Company’s objectives, plans or goals are,
or may be, forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from Catalent, Inc.’s expectations and
projections. Some of the factors that could cause actual results to
differ include, but are not limited to, the following: participation in
a highly competitive market and increased competition may adversely
affect the business of the Company; demand for the Company’s offerings
which depends in part on the Company’s customers’ research and
development and the clinical and market success of their products;
product and other liability risks that could adversely affect the
Company’s results of operations, financial condition, liquidity and cash
flows; failure to comply with existing and future regulatory
requirements; failure to provide quality offerings to customers could
have an adverse effect on the Company’s business and subject it to
regulatory actions and costly litigation; problems providing the highly
exacting and complex services or support required; global economic,
political and regulatory risks to the operations of the Company;
inability to enhance existing or introduce new technology or service
offerings in a timely manner; inadequate patents, copyrights, trademarks
and other forms of intellectual property protections; fluctuations in
the costs, availability, and suitability of the components of the
products the Company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials; changes
in market access or healthcare reimbursement in the United States or
internationally; fluctuations in the exchange rate of the U.S. dollar
and other foreign currencies including as a result of the recent U.K.
referendum to exit from the European Union; adverse tax legislation
initiatives or challenges to the Company’s tax positions; loss of key
personnel; risks generally associated with information systems;
inability to complete any future acquisitions and other transactions
that may complement or expand the business of the Company or divest of
non-strategic businesses or assets and the Company’s ability to
successfully integrate acquired business and realize anticipated
benefits of such acquisitions; offerings and customers’ products that
may infringe on the intellectual property rights of third parties;
environmental, health and safety laws and regulations, which could
increase costs and restrict operations; labor and employment laws and
regulations; additional cash contributions required to fund the
Company’s existing pension plans; substantial leverage resulting in the
limited ability of the Company to raise additional capital to fund
operations and react to changes in the economy or in the industry,
exposure to interest rate risk to the extent of the Company’s variable
rate debt and preventing the Company from meeting its obligations under
its indebtedness. For a more detailed discussion of these and other
factors, see the information under the caption “Risk Factors” in the
Company’s Annual Report on Form 10-K for the fiscal year ended June 30,
2016, filed with the Securities and Exchange Commission. All
forward-looking statements speak only as of the date of this release or
as of the date they are made, and Catalent, Inc. does not undertake to
update any forward-looking statement as a result of new information or
future events or developments except to the extent required by law.
More products. Better treatments. Reliably supplied.™
For Catalent, Inc.
Investors:
Thomas Castellano, +1-732-537-6325
[email protected]
or
Media:
Chris Halling, +44 (0)7580 041073
[email protected]
or
Richard Kerns, +44 (0) 161 728 5880
[email protected]